Product Information
KISQALI 400 MG DAILY DOSE is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $346.9469 per EA under NDC 00078086742. Its NADAC has been published 28 times since Dec 17, 2025.
Strength
200 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078086742
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
RIBOCICLIB SUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA209092On Market Since
3/13/2017
Pharmacological Classes
Price Statistics
The NADAC for KISQALI 400 MG DAILY DOSE has been published 28 times since Dec 17, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $346.9469 per EA |
|---|---|
| All-time high | $347.4053 (Apr 15, 2026) |
| All-time low | $346.9384 (Apr 22, 2026) |
| 52-week high | $347.4053 |
| 52-week low | $346.9384 |
| Median price | $347.4053 |
| Average price | $347.2403 |
| Largest weekly change | -0.1% (Apr 22, 2026) |
| Weeks tracked | 28 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 16% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of KISQALI 400 MG DAILY DOSE?
The current National Average Drug Acquisition Cost (NADAC) for KISQALI 400 MG DAILY DOSE, manufactured by Novartis Pharmaceuticals Corporation, is $346.9469 per EA (NDC 00078086742), effective Jun 24, 2026.
How has the price of KISQALI 400 MG DAILY DOSE changed over time?
Over the history we have for it, the NADAC for KISQALI 400 MG DAILY DOSE has held within roughly two percent of its current level. It has been tracked across 28 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for KISQALI 400 MG DAILY DOSE?
Since Dec 17, 2025, the NADAC for KISQALI 400 MG DAILY DOSE has ranged from a low of $346.9384 (Apr 22, 2026) to a high of $347.4053 (Apr 15, 2026), with a median of $347.4053 per EA.
Are there cheaper alternatives to KISQALI 400 MG DAILY DOSE?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, KISQALI 600 MG DAILY DOSE, is $289.7167 per EA — about 16% below KISQALI 400 MG DAILY DOSE.
Who manufactures KISQALI 400 MG DAILY DOSE?
KISQALI 400 MG DAILY DOSE (NDC 00078086742) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.
Related Drugs
Same classification